arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Polaryx Therapeutics, Inc.

PLYX
$2.28 ▲ +0.11 (+5.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
3 Visible periods
17 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Polaryx Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $103.6M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -135.3%
FCF / Share $-0.09
Trailing P/E
Price / Book 23.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-8.98M
↑ +70.4%
FCF / Share Free cash flow per share
$-0.09
↓ -15.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
3
Cash Quality
37

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 5 quarters